Test Price
2,800 AED✅ Home Collection Available
CDH1 Hereditary Diffuse Gastric Cancer Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity for single nucleotide variants and small insertions/deletions via ISO 9001:2015 accredited NGS workflow (Cert: INT/EGQ/2509DA/3139).
- Specimen Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection — available daily from 8 AM to 11 PM.
- Post-Test Support: Telephonic clinical guidance with a DHA-licensed consultant medical geneticist for result interpretation and pedigree-based risk stratification.
- Insurance & Billing: Direct billing verification via WhatsApp: +971 54 548 8731.
- DHA Governance: Facility License 1143, Dubai Healthcare City, strictly adhering to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Test Overview & Methodology
The CDH1 NGS Test identifies pathogenic germline variants in the CDH1 gene responsible for Hereditary Diffuse Gastric Cancer (HDGC). Detection of a deleterious mutation enables risk-reducing interventions, including prophylactic total gastrectomy and intensified endoscopic surveillance. The assay covers all coding exons, intron-exon boundaries, and detects copy number variants (CNVs) that Sanger sequencing cannot resolve.
| Feature | DNA Labs UAE NGS Test | Conventional Sanger Sequencing |
|---|---|---|
| Genomic Coverage | Full CDH1 gene (all exons + flanking splice regions) | Hotspot exons only; no CNV detection |
| Technology | Next-Generation Sequencing with bioinformatic CNV calling | Capillary electrophoresis; no deletion/duplication analysis |
| Turnaround Time | 21–28 calendar days | 42–56 calendar days |
| Variant Detection Rate | >99.9% for SNVs and indels; >95% for CNVs | ~95% for point mutations in targeted exons only |
Physician Insight & Safety Protocols
"A confirmed pathogenic variant in the CDH1 gene represents a clinically actionable finding that mandates structured genetic counseling and multidisciplinary risk management. Patients should undergo comprehensive pedigree analysis prior to testing, and post-test interpretation must be contextualized within family history and endoscopic surveillance findings. This molecular assessment is a diagnostic adjunct — no therapeutic decisions should be made without consultation with your managing clinical geneticist."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory Precautions for Test Candidates
- Medication Continuity: Do not alter or discontinue any prescribed therapy without direct consultation with your treating physician.
- Emergency Symptoms: Epigastric pain refractory to standard care, hematemesis, melena, or unintentional weight loss exceeding 5% over one month require immediate emergency evaluation — do not await genetic results.
- Pregnancy & Lactation: Venipuncture is safe during pregnancy; however, pre-test genetic counseling must address reproductive implications of a positive finding.
Exclusion Criteria for Home Collection
- Minors (under 18): Testing requires court-appointed legal guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Clinical Instability: Individuals currently hospitalized for acute medical or surgical conditions must arrange collection through their attending hospital — mobile phlebotomy is not available in inpatient settings.
- Prior Gastrectomy: Patients who have undergone total gastrectomy remain eligible for genetic testing, but the clinical utility of surveillance endoscopy is obviated; counseling should address hereditary cancer risks in remaining tissues and family cascade screening.
Patient FAQ & Clinical Guidance
1. What is the CDH1 gene and how does it cause hereditary gastric cancer?
The CDH1 gene encodes E-cadherin, a transmembrane protein critical for epithelial cell adhesion. Germline loss-of-function mutations disrupt this adhesion, leading to diffuse-type gastric carcinoma that infiltrates the stomach wall without forming a discrete mass. Lifetime gastric cancer risk for CDH1 mutation carriers ranges from 40% to 70%, with female carriers also facing elevated risk for lobular breast cancer. Identification of a pathogenic variant enables risk-reducing total gastrectomy, which can be curative if performed before malignancy develops.
2. Who meets the clinical criteria for CDH1 genetic testing?
Testing is indicated for individuals meeting any of the following: two or more cases of diffuse gastric cancer in first- or second-degree relatives (any age); one case of diffuse gastric cancer before age 40; personal or family history of diffuse gastric cancer and lobular breast cancer (one diagnosis before age 50); or a known CDH1 mutation in a blood relative. Pre-test genetic counseling with a qualified medical geneticist is mandatory to document pedigree structure and obtain informed consent.
3. How is the specimen collected and what is the testing timeline?
A licensed DHA phlebotomist collects a venous whole blood sample (two 6 mL EDTA tubes), an oral buccal swab, or an FTA card at your residence using temperature-controlled cold-chain transport. No fasting or dietary preparation is required. The sample is processed by our ISO 9001:2015 accredited laboratory with NGS analysis covering all CDH1 coding exons and CNV assessment. Final results are delivered within 21–28 calendar days, accompanied by a telephonic interpretation session with the referring consultant medical geneticist.
4. What do the results mean for my family members?
A positive finding confirms a hereditary cancer syndrome with autosomal dominant inheritance. First-degree relatives (parents, siblings, children) have a 50% chance of carrying the same mutation. Cascade testing for at-risk relatives is strongly recommended to identify those who would benefit from prophylactic gastrectomy or intensive surveillance. Our genetic counseling team facilitates family variant testing and coordinates with referring gastroenterologists and oncologists for integrated management planning.
UAE Regulatory & Data Privacy Adherence
Legal & Compliance Framework
All genetic testing procedures at DNA Labs UAE are conducted in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient genomic data is encrypted, access-controlled, and stored on UAE-based servers. Clinical safety and informed consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. Our quality management system is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
For billing inquiries or to verify direct insurance coverage, contact us via WhatsApp at +971 54 548 8731 (daily 8 AM – 11 PM).
Clinical & Logistical Metadata
| Test Name | CDH1 Gene Mutation Analysis (Hereditary Diffuse Gastric Cancer) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 calendar days |
| Sample Type / Matrix | Whole blood (EDTA), buccal swab, or FTA card |
| Methodology Used | Next-Generation Sequencing (NGS) — full gene sequencing with copy number variant analysis |
| ICD-10-CM Code | Z15.09 (Genetic susceptibility to other malignant neoplasm) |
| LOINC Code | 21636-6 (CDH1 gene mutation analysis) |
| DHA Facility License & Address | DHA License 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians